Home >> Signaling Pathways >> Tyrosine Kinase >> Bcr-Abl

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Products for  Bcr-Abl

  1. Cat.No. Product Name Information
  2. GC12172 1-Naphthyl PP1

    1NaphthylPP1, PP1 Analog

    Src family kinases inhibitor 1-Naphthyl PP1  Chemical Structure
  3. GC15579 Adaphostin

    NSC 680410

    P210bcr/abl tyrosine kinase inhibitor Adaphostin  Chemical Structure
  4. GC11737 AG957

    NSC 654705,Tyrphostin AG957

    a tyrphostin that targets transforming Bcr-Abl fusion proteins AG957  Chemical Structure
  5. GC32703 Asciminib (ABL001)

    ABL001

    Asciminib (ABL001) (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib (ABL001)  Chemical Structure
  6. GC64462 Asciminib hydrochloride Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib hydrochloride  Chemical Structure
  7. GC10914 AST 487

    NVP-AST 487

    A multi-kinase inhibitor AST 487  Chemical Structure
  8. GC10638 AT9283 A broad spectrum kinase inhibitor AT9283  Chemical Structure
  9. GC35462 Bafetinib

    INNO-406

    Bcr-Abl/Lyn tyrosine kinase inhibitor

    Bafetinib  Chemical Structure
  10. GC33343 BCR-ABL-IN-1 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. BCR-ABL-IN-1  Chemical Structure
  11. GC33368 BCR-ABL-IN-2 BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. BCR-ABL-IN-2  Chemical Structure
  12. GC13343 Bosutinib (SKI-606)

    SKI 606

    Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively. Bosutinib (SKI-606)  Chemical Structure
  13. GC40080 Bosutinib-d8

    SKI-606 D8

    Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS. Bosutinib-d8  Chemical Structure
  14. GC43198 CAY10717 CAY10717 is a multi-targeted kinase inhibitor that exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM. CAY10717  Chemical Structure
  15. GC35651 Cenisertib

    AS-703569; R-763

    Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib  Chemical Structure
  16. GC17294 CHMFL-ABL-053 BCR-ABL inhibitor CHMFL-ABL-053  Chemical Structure
  17. GC35682 CHMFL-ABL/KIT-155

    CHMFL-ABL-KIT-155

    CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis. CHMFL-ABL/KIT-155  Chemical Structure
  18. GC35753 CT-721 CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. CT-721  Chemical Structure
  19. GC33351 CZC-8004 (CZC-00008004)

    Dianilinopyrimidine-01

    CZC-8004 (CZC-00008004) (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 (CZC-00008004) can bind a range of tyrosine kinases, including EGFR and VEGFR2 with IC50 values of 650 and 437 nM, respectively. CZC-8004 (CZC-00008004)  Chemical Structure
  20. GC15568 Dasatinib (BMS-354825)

    BMS 354825, Sprycel

    An inhibitor of Abl and Src Dasatinib (BMS-354825)  Chemical Structure
  21. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor Dasatinib hydrochloride  Chemical Structure
  22. GC15884 Dasatinib Monohydrate Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. Dasatinib Monohydrate  Chemical Structure
  23. GC45687 Dasatinib N-oxide A major metabolite of dasatinib Dasatinib N-oxide  Chemical Structure
  24. GC14007 DCC-2036 (Rebastinib)

    DCC-2036

    DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib)  Chemical Structure
  25. GC35897 DPH A potent cell permeable c-Abl activator DPH  Chemical Structure
  26. GC32867 Flumatinib (HHGV678)

    HH-GV-678

    Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HHGV678)  Chemical Structure
  27. GC13914 Flumatinib mesylate PDGRFβ inhibitor Flumatinib mesylate  Chemical Structure
  28. GC36167 GMB-475 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein. GMB-475  Chemical Structure
  29. GC10858 GNF 2

    Bcr-Abl Inhibitor

    Bcr-Abl inhibitor GNF 2  Chemical Structure
  30. GC15079 GNF 5 Bcr-Abl inhibitor GNF 5  Chemical Structure
  31. GC10607 GNF-7

    Type II Bcr-Abl inhibitor

    GNF-7  Chemical Structure
  32. GC10915 GZD824

    GZD824 dimesylate; HQP1351 dimesylate

    Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. GZD824 potently inhibits a broad spectrum of Bcr-Abl mutants. GZD824 strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. GZD824 has antitumor activity. GZD824  Chemical Structure
  33. GC33201 GZD856 GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856  Chemical Structure
  34. GC62453 GZD856 formic GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 formic  Chemical Structure
  35. GC71477 HG-7-86-01 HG-7-86-01 (Compound 26) is type II tyrosine kinase inhibitor. HG-7-86-01  Chemical Structure
  36. GC10314 Imatinib (STI571) Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib (STI571)  Chemical Structure
  37. GC60930 Imatinib D4 Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D4  Chemical Structure
  38. GC39612 Imatinib D8 Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D8  Chemical Structure
  39. GC11759 Imatinib Mesylate (STI571)

    CGP57148B, STI571

    Imatinib Mesylate (STI571) (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases. Imatinib Mesylate (STI571)  Chemical Structure
  40. GC47452 Imatinib-d3

    Genfatinib-d3

    Imatinib-d3 (STI571-d3) hydrochloride is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib-d3  Chemical Structure
  41. GC14592 KW 2449 A multi-kinase inhibitor KW 2449  Chemical Structure
  42. GC69418 Lyn-IN-1

    Bafetinib analog

    Lyn-IN-1 (Bafetinib analog) is a highly active dual inhibitor of Bcr-Abl and Lyn.

    Lyn-IN-1  Chemical Structure
  43. GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1 NG 25 (hydrochloride hydrate)  Chemical Structure
  44. GC60270 Nilotinib D6 An internal standard for the quantification of nilotinib Nilotinib D6  Chemical Structure
  45. GC25669 Nilotinib hydrochloride

    AMN-107 HCl

    Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Nilotinib hydrochloride  Chemical Structure
  46. GC14237 Nilotinib monohydrochloride monohydrate A Bcr-Abl inhibitor Nilotinib monohydrochloride monohydrate  Chemical Structure
  47. GC14129 Nilotinib(AMN-107)

    AMN107

    Nilotinib(AMN-107) is a selective oral tyrosine kinase inhibitor that inhibits the autophosphorylation of native Bcr-Abl (WT p210) and mutant Bcr-Abl (E281K, E292K, F317L, M351T, and F486S) with IC50 values of 20, 42, 31, 38, 29, and 41nM, respectively. Nilotinib(AMN-107)  Chemical Structure
  48. GC14075 Nocodazole

    NSC 238159, Oncodazole, R 17934

    Nocodazole is an anti-mitotic drug and a rapid and reversible microtubule polymerization inhibitor. It inhibits Abl, Abl (E255K), and Abl (T315I) in cell-free assays with IC50 values of 0.21μM, 0.53μM, and 0.64μM, respectively. Nocodazole  Chemical Structure
  49. GC62207 Olverembatinib

    GZD824; HQP1351

    Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity. Olverembatinib  Chemical Structure
  50. GC36807 ON 146040 ON 146040 is a potent PI3Kα and PI3Kδ (IC50≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits Abl1 (IC50<150 nM). ON 146040  Chemical Structure
  51. GC15314 PD 166326 receptor tyrosine kinases inhibitor PD 166326  Chemical Structure
  52. GC12637 PD 180970 P210bcr/abl tyrosine kinase inhibitor PD 180970  Chemical Structure
  53. GC13592 PD173955 Dual Src/Abl kinase inhibitor, ATP-competitive, PD173955  Chemical Structure
  54. GC14396 Ponatinib (AP24534)

    AP 24534

    Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534)  Chemical Structure
  55. GC52104 Ponatinib (hydrochloride)

    AP 24534

    An inhibitor of native and mutant Bcr-Abl Ponatinib (hydrochloride)  Chemical Structure
  56. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8  Chemical Structure
  57. GC12779 PPY A Abl kinases inhibitor PPY A  Chemical Structure
  58. GC11140 Radotinib(IY-5511)

    IY-5511

    Bcr-Abl tyrosine kinase inhibitor Radotinib(IY-5511)  Chemical Structure
  59. GC63332 S116836 S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies. S116836  Chemical Structure
  60. GC15197 Saracatinib (AZD0530)

    AZD 0530

    Saracatinib (AZD0530) (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib (AZD0530) shows high selectivity over other tyrosine kinases. Saracatinib (AZD0530)  Chemical Structure
  61. GC65592 SNIPER(ABL)-020 SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein. SNIPER(ABL)-020  Chemical Structure
  62. GC70110 Vamotinib

    PF-114

    Vamotinib (PF-114) is an effective, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the self-phosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib exhibits anti-proliferative and anti-tumor activity. Vamotinib has potential in the study of resistant Philadelphia chromosome-positive (Ph+) leukemia.

    Vamotinib  Chemical Structure
  63. GC62103 Vodobatinib

    K0706

    Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research. Vodobatinib  Chemical Structure
  64. GC10970 WP1130

    WP 1130; WP-1130

    WP1130 (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. WP1130 has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2. WP1130  Chemical Structure
  65. GC13102 XL228 A tyrosine kinase inhibitor XL228  Chemical Structure

64 Item(s)

per page

Set Descending Direction